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Abstract
Background: Liver fibrosis ranks as the second cause of death in México's productive-age population. This pathology 
is characterized by acummulation of fibrillar proteins in hepatic parenchyma causing synthetic and metabolic 
disfunction. Remotion of excessive fibrous proteins might result in benefit for subjects increasing survival index. The 
goal of this work was to find whether the already known therapeutical effect of human urokinase Plasminogen 
Activator and human Matrix Metalloprotease 8 extends survival index in cirrhotic animals.
Methods: Wistar rats (80 g) underwent chronic intoxication with CCl4: mineral oil for 8 weeks. Cirrhotic animals were 
injected with a combined dose of Ad-delta-huPA plus Ad-MMP8 (3 × 1011 and 1.5 × 1011 vp/Kg, respectively) or with 
Ad-beta-Gal (4.5 × 1011) and were killed after 2, 4, 6, 8 and 10 days. Then, liver and serum were collected. An additional 
set of cirrhotic animals injected with combined gene therapy was also monitored for their probability of survival.
Results: Only the cirrhotic animals treated with therapeutical genes (Ad-delta-huPA+Ad-MMP-8) showed 
improvement in liver fibrosis. These results correlated with hydroxyproline determinations. A significant decrement in 
alpha-SMA and TGF-beta1 gene expression was also observed. Cirrhotic rats treated with Ad-delta-huPA plus Ad-MMP8 
had a higher probability of survival at 60 days with respect to Ad-beta-Gal-injected animals.
Conclusion: A single administration of Ad-delta-huPA plus Ad-MMP-8 is efficient to induce fibrosis regression and 
increase survival in experimental liver fibrosis.
Background
Advanced liver fibrosis and/or cirrhosis, represent a
worldwide health problem. In México, represent the 2nd
cause of dead in productive-age population [1]. This
pathology is consequence of a sustained chronic hepatic
injury by a variety of causes including viral, chronic alco-
hol abuse and cholestasis induced by prolonged biliary
obstruction [2,3].
Multiple factors influencing survival of patients with
hepatic cirrhosis are invoked. Etiology is the principal
determinant, though, factors as age, life style and the
presence of complications at moment of diagnosis (asci-
tis, ictericia, encephalopathy, variceal haemorrhage and
others) impact in the survival of these patients [3].
Accumulation of extracellular matrix (ECM) proteins
distorts the hepatic architecture by forming a fibrous
scar, and the subsequent development of nodules of
regenerating hepatocytes defines cirrhosis. Cirrhosis pro-
duces hepatocellular dysfunction and increased intrahe-
patic resistance to blood flow, which result in hepatic
insufficiency and portal hypertension [2,4].
Currently, therapeutic repertoire for liver fibrosis and
cirrhosis treatment is limited. Broadly, treatment falls
into two categories; removal of the underlying injurious
stimulus (where possible), such as viral eradication in
hepatitis B- and C-mediated liver disease, and liver trans-
plantation, though with existing disadvantage [4,5].
Central to fibrogenesis and the scarring of organs is the
activation of tissue fibroblasts into ECM-secreting myofi-
broblasts. Within the liver, the main effector cells of
fibrosis are activated-hepatic stellate cells (aHSC), that
express (among other pro-fibrogenic molecules) TGF-β
and secrete fibrillar collagens, resulting in the deposition
* Correspondence: armdbo@gmail.com
1 Institute for Molecular Biology in Medicine and Gene Therapy, University of 
Guadalajara, Department of Molecular Biology and Genomics, Sierra Mojada St. 
#950, Guadalajara (44280), Mexico
Full list of author information is available at the end of the articleBioMed Central
© 2010 Gálvez-Gastélum et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Gálvez-Gastélum et al. Journal of Biomedical Science 2010, 17:42
http://www.jbiomedsci.com/content/17/1/42
Page 2 of 9of fibrotic matrix. HSC also express TIMP with the result
that ECM-degrading metalloproteinase activity is inhib-
ited. This alters the balance and renders ECM accumula-
tion [2,4,6].
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent proteolytic enzymes which comprise 22 differ-
ent members. These can degrade virtually all the constit-
uents of the ECM [7,8]. Although all of them exhibit a
broad substrate spectrum, they are divided based on their
main substrate into collagenases, gelatinases,
stromelysins, matrilysins, metalloelastases, membrane-
type MMPs (MT-MMPs), and others [8]. In particular
MMP-8 is a neutrophil collagenase that avidly degrades
ECM preferently type I collagen [9].
Urokinase-type plasminogen activator (uPA), lies at the
top of the proteolytic cascade of the plasminogen/plas-
min system, and acts to generate plasmin from circulat-
ing plasminogen by proteolytic cleavage. Plasmin is a
broad-spectrum proteinase capable of degrading matrix
components directly, and inhibiting deposition of ECM
indirectly by activating MMPs secreted in latent inactive
forms (in particular pro-MMP1, pro-MMP-3, pro- MMP-
9 and pro-MMP-2) [10,11]. Both, MMP-8 and uPA
cDNAs have been deviced as therapeutic agents cloned in
adenoviral vectors [2,3,9-12]. Their molecular mecha-
nisms have separately been extensively described in dif-
ferent models of experimental cirrhosis.
Because of the regenerative ability and hepatic function
are impaired, the remotion of excessive fibrous proteins
deposited in the Disse's space and the acceleration of
remnant hepatic-mass regeneration, might result in bene-
fit for subjects undergoing liver fibrosis due to the func-
tional re-establishment of the hepatocyte-sinusoid flow
exchange. Thus, the goal of this work was to search for
the combinatorial effect of gene therapy with adenoviral
vectors containing cDNAs for huPA and MMP-8 (Ad-




Wistar rats, weighing 80 g were made cirrhotic according
to Perez-Tamayo R [13]. Then, cirrhotic animals were
injected with a dose of combined gene therapy of Ad-
ΔhuPA plus Ad-MMP8 (3 × 1011 and 1.5 × 1011 v.p/Kg,
respectively) and Ad-β-Gal (4.5 × 1011) as irrelevant gene
(n = 25 in each experimental group), and were sacrificed
at 2, 4, 6, 8 and 10 days after treatment (Figure 1A). At the
end of each time period, biological samples (liver, serum,
plasma) were obtained for molecular and histological
analysis. Four more groups were included for the survival
analysis (n = 14) (Figure 1B). It is important to notice that
the administration of CCl4 was continued up to the end of
the experiments in all groups.
Adenoviral vectors
Worthwhile mentioning, the amount of viral particles of
Ad-β-Gal used was identical to the sum of the number of
viral particles represented by Ad-huPA and Ad-MMP-8
in order to eliminate experimental artifacts, and to dem-
onstrate that the observed effects were the result of both
therapeutic transgenes, and not the result of combining
both adenoviruses. The three Ad vectors used were man-
ufactured according to Salgado et al. [14] and Siller et al.
[9], under GMPs, GCPs and GLPs.
Transgene expression and activity assays
Protein extraction and determination were carried out
with double- detergent and Bradford metodology, respec-
tivelly. For detection of human MMP8 activity we utilized
a comercial kit of Biotrak (Amersham Biosciences, Buck-
inghamshire, UK). Determination was realized with 40 μg
of total proteins of cirrhotic livers-homogenated at 405
nm. For evaluation of MMP-2 and MMP-9 activity we
used 40 μg of total protein in each experimental group,
according to out previous communication [10]. Human
uPA activity was determined using the same methodol-
ogy, except that gels were covered with casein (1 mg/ml)
and plasmingen (1 mg/ml) as substrate.
Morphometric analysis
For histological study in each experimental group, liver
sections were fixed by immersion in 4% paraformalde-
hyde diluted in phosphate buffered saline (PBS), dehy-
drated in graded ethylic alcohol and embedded in
paraffin. Briefly, sections 6 μm thick were stained with
Masson trichromic to determine amount of liver tissue
affected by extracellular matrix. Then, by using a com-
puter-assisted automated image analyzer ProPlus (Media
Cybernetics, Silver Spring, Md) 20 random fields per
slide were analysed and the ratio of connective tissue to
the whole liver area was calculated. Results are expresed
in mean ± standard deviation.
Hydroxyproline determination
Liver samples were obtained at the moment of death, and
150 mg of tissue were frozen, weighed and minced into a
fine homogenous mixture. Hepatic tissue (1 mg) was
hydrolyzed with 2 ml 6N HCl for 12 h at 100°C. Hydroxy-
proline content of each sample was determined by a colo-
rimetric assay described earlier. Briefly, the reaction was
started by adding 1 ml of Chloramine-T solution to 1 ml
of sample and 4 ml of Erlich's reactive (dimethylbenzalde-
hyde acid solution) [15]. After an incubation period of 30
min at room temperature (25-30°C), the optical density
(OD) was determined within 30 min at a wavelength of
560 nm. The results were calculated as percent of colla-
gen in wet liver weigh, using hydroxyproline standards
(Sigma-Aldrich, Munich, Germany).
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Blood was drawn from control and experimental cir-
rhotic animals treated with therapeutical genes at the
moment of sacrifice and serum transaminases (ALT and
AST), albumin and bilirrubins were determined in an
automated Syncron-Cx7 machine at Hospital Civil de
Guadalajara.
Immunohistochemical determinations
Hepatic tissue sections were deparaffinized and rehy-
drated with xylene and decreasing graded ethanol. Slides
were incubated in 3% H2O2 for 10 min, followed by incu-
bation with polyclonal anti-goat against human uPA
(Chemicon International, USA) diluted in PBS (1/400), or
incubation with polyclonal antibody anti-goat against
human MMP8 (Chemicon International, Temecula, CA,
USA) diluted in PBS (1/600). Similarly, the most impor-
tant proteins implicated in cellular proliferation were
determined with either monoclonal anti-mouse PCNA
antibody (Sigma Aldrich, Ltd, Dorset, UK) or HGF
(Sigma Aldrich, Ltd, Dorset, UK) or c-met (Sigma Aldrich
St. Louis, MO) all antibodies were diluted 1/200 in PBS.
Marker for HSC activation was determined by a mono-
clonal anti-mouse antibody against α-SMA (Boehringer
Manheim, Germany) diluted 1/50. Primary antibodies
were incubated at 4°C overnight, followed by incubation
with biotinylated secondary antibodies. Secondary anti-
bodies were complexed individually with avidin-conju-
gated peroxidase Vectastain ABC-Elite reagent (Vector
Laboratories, Burlingame, CA USA) and resulting peroxi-
dase activity was detected with 3,30-diaminobenzidine
(DAKO) in sections that were briefly counterstained with
hematoxylin. Positive cells were analized in 20 random
fields of pericentral, mid-zonal and periportal areas. Cell
counting was carried out in a software-automated
(Image-Proplus Analyzer, Qwin-Leica, USA).
Figure 1 Experimental design. Rats were made cirrhotic with different CCl4: mineral oil dilutions during seven weeks. After the animals were treated 
with the combined gene therapy, they were continuosly injected (three times a week) with the hepatoxin. When indicated, serum and liver extracts 
were obtained for the determinations specified in Materials and Methods.
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Gene expression for TGF-β, HGF, c-met and HPRT (con-
stitutive gene) was analyzed by semicuantitative PCR
(RT-PCR). RNA extraction was performed by fenol cloro-
form metodology as reported previously. Retrotranscrip-
tion was mounted using 2 μg of total RNA and 400 U of
M-MLV reverse transcriptase (Gibco, Life Technologies
Ltd., Paisley). After that, 2 μl of cDNA plus 48 μl of an
solution containing 10× buffer of MgCl2 50 mM, 2500 μM
dNTPs, 3 μM oligonucleotides, 1U Taq Polimerase
(Gibco, Life Technologies Rockville, MD).
The reaction was performed on a Perkin-Elmer DNA
Termal Cycler 480, at 94°C (5 mins), 95°C (1 min), 60°C (1
min) and 72°C (1.5 mins). Alignment temperature for
HGF was 58°C (1.5 mins). Oligonucleotides utilized are
shown in Table 1.
Survival analysis
Four additional groups composed by rats with liver fibro-
sis (n = 14) treated with Ad-β-gal (4.5 × 1011vp/kg), Ad-
ΔhuPA + Ad-MMP8 (3 and 1.5 × 1011vp/kg, respectively),
only Ad-MMP-8 (1.5 × 1011vp/kg) and only Ad-ΔhuPA (3
× 1011vp/kg) were also monitored for their probability of
survival.
Statistical analysis
Data are shown as mean ± SD. Differences between
experimental groups and controls were analyzed with
ANOVA test. Survival rates were estimated by the
Kaplan-Meier method, and differences were analyzed
with the log rank test to compare the resulting curves of
treatment groups. A probability value of < 0.05 was con-
sidered statistically significant (SPSS version 10.0).
Results
Reduction of hepatic fibrosis at the end of the experiment
(8 and 10 days) resulted in morphological improvement,
where a smooth hepatic texture in normal and combined
gene therapy-treated cirrhotic rats is conspicuous, as
compared with the rough and granular liver surface from
Ad-β-Gal-injected animals (Figure 2A). Furthermore,
these findings were accompanied by a clear improvement
in collateral circulation and gastric varices, suggesting
diminished intrahepatic blood pressure in animals
injected with Ad-huPA plus Ad-MMP-8 (data no show).
Severe accumulation of peritoneal fluid and important
clinical manifestations of advanced hepatic cirrhosis were
detected in all animals treated with Ad-β-Gal. All cir-
rhotic animals injected with Ad-huPA plus Ad-MMP8
showed moderate ascites. Functional hepatic tests were
notably normalized, after six days of treatment with the
therapeutical combination (ALT 43% and AST decreased
75%) compared with cirrhotic animals treated with Ad-β-
Gal (Figure 2B).
Collagen content, as measured by the fibrosis index,
demonstrated that only cirrhotic animals treated with
therapeutical combination showed a significative regres-
sion of fibrosis. Hydroxyproline content decreased in cir-
rhotic animals treated with Ad-huPA plus Ad-MMP8
compared with the group administered with Ad-β-Gal.
As shown in Figure 3A, the most important regression of
fibrosis was at 4 days after administration of therapeutical
vectors. To corroborate these findings, we realized histo-
morphometric analysis that showed less ECM-accumula-
tion in the animals treated with Ad-huPA plus Ad-MMP-
8 at the 6th day (50%), (Figure 3B and 3C). Gene expres-
sion of the most important profibrogenic-cytokine (TGF-
β) was significantly diminished in this same group of ani-
mals treated with therapeutic adenoviral vectors (60% of
decrement at 8th day), (Figure 3D).
Immunohistochemical determination of human
trangenes (huPA and MMP-8) was performed in each
experimental group. A significative increment of the cor-
responding proteins was observed at 4 day after thera-
peutical vectors injection to cirrhotic animals as
compared with the group of rats treated with irrelevant
control, demonstrating an efficient transduction of aden-
oviral vectors, (Figure 4A and 4B). Then, we proceeded to
determine the actual biological activity shown by human
uPA that had a molecular migration at 54 kDa. Similarly,
the major activity of transgenes was observed at 4 days
after administration of vectors (Figure 4C). The activity of
MMP2 and MMP9 significantly increased at 4 day after
treatment in experimental group treated with Ad-huPA
plus Ad-MMP-8 and correlated with the presence and
activity of human transgenes transduced by Ad vectors
(huPA and MMP-8). Figure 4D, clearly shows activity for
both matrix metalloproteinase's (MMP-2; 72 kDa and
MMP-9; 92 kDa).
Hepatic cells proliferation determined by anti-PCNA
immunohistochemical revealed an increment (50%) in
Table 1: Primers sequence utilized in the semiquantitative 
RT-PCR
Gene Primers
HPRT S 5' TCCCAGCGTCGTGATTAGTG 3'
A 3' GGCTTTTCCACTTTCGCTGA 5'
HGF S 5' ATGCTCATGGACCCTGGT 3'
A 3' GCCTGGCAAGCTTCATTA 5'
c-met S 5' CAGTGATGATCTCAATGGGCAAT 3'
A 3' AATGCCCTCTTCCTATGACTTC 5'
TGF-β1 S 5' GCCTCCGCATCCCACCTTTG 3'
A 3' GCGGGTGACTTCTTTGGCGT 5'
Gálvez-Gastélum et al. Journal of Biomedical Science 2010, 17:42
http://www.jbiomedsci.com/content/17/1/42
Page 5 of 9the number of hepatocytes of animals receiving combina-
torial gene therapy during the first four days of treatment
(at 2 and 4 days of sacrifice). Number of PCNA positive
cells began to decrease afterwards (Figure 5A). Figure 5B
shows gene expression for HGF and its cognate receptor
c-met determined by semiquantitative RT-PCR. Only cir-
rhotic animals treated with AdhuPA plus AdMMP-8
shown decrement of number of activated-HSC (α-SMA+)
as of the fourth day (Figure 5C).
Finally, the most relevant piece of data shown here is
the determination of survival, which was significative
only in cirrhotic animals that recover after the treatment
with the combined therapeutic vectors (about 30% of
recovery). The surviving animals reached 60 days after
combinatorial therapy as compared with only 35 to 40
days displayed by animals injected either with irrelevant
vectors or mono therapy, (Figure 5D).
Discussion
Liver cirrhosis is becoming an increasing health problem;
patients with liver cirrhosis have a high mortality, not just
from cirrhosis-related causes, but also from other causes.
This observation indicates that many patients with cir-
rhosis have other chronic diseases, yet the prognostic
impact of co-morbidities has not been examined [16].
Common causes of liver cirrhosis include hepatitis B,
hepatitis C, alcohol abuse as well as non-alcoholic steato-
hepatitis and hereditary metabolic defects. Liver cirrhosis
has a considerable impact on surgical practice [17].
Liver fibrosis refers to the accumulation of interstitial
ECM (scar) after chronic hepatic injury. Septum forma-
tion and rings of scar that surround nodules of hepato-
cytes characterize cirrhosis, the end-stage of progressive
fibrosis. These structural alterations that repel in the
architecture of liver are characterized by an alteration in
the wound healing of ECM, conversion of HSC into acti-
Figure 2 Macroscopic aspect of liver and functional hepatic tests. A, a) a representative image a normal rat liver, b and c shows a recovered he-
patic smooth texture in animals treated with the combinatorial gene therapy at 8 and 10 days, respectively, as compared with irrelevant gene therapy 
(e and f), d) shows a control fibrotic liver injected with saline. Histograms in B, show a significative tendency to normal values of hepatic functional 
tests (ALT and AST).
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tive arrest [6,11]. These alterations have been derived of
genetic overexpression or down-regulation in the activity
of enzymes participating in the normal mechanisms of
ECM degradation (metalloproteases) Also, can be caused
by growth factors (TGF-β or PDGF) influencing HSC
activation characterized by the acquisition of a prolifera-
tive, contractile, migratory, fibrogenic and inflammatory
phenotype [6]. To experimentally reproduce these altera-
tions, several approaches for induction of fibrosis have
been described. Of these, CCl4 chronic intoxication in
rats and mice is probably the most widely studied. In
addition, CCl4 model is the best characterized with
respect to histological, biochemical, cellular, and molecu-
lar changes associated with the development of human
hepatic fibrosis. CCl4 given intraperitoneally induces
hepatocyte necrosis and apoptosis with associated HSC
activation and tissue fibrosis. The ongoing treatment
with CCl4 can be used to induce hepatic fibrosis (4
weeks), cirrhosis (8 weeks) and advanced micronodular
cirrhosis (12 weeks) [5]. In this experimental work the
results showed a timing onset of hepatic fibrosis charac-
terized by distortion of normal architecture of liver, with
extensive fibrous proteins (scarring) that create fibrotic-
bridges between contiguos hepatic lobules, HSCs activa-
tion, decrement in metalloproteases function, increment
of TGF-β1 gene expression and fibrillary proteins. Rever-
sal of these processes (histological, biochemical, cellular,
and molecular) has become the focus in the treatment of
liver fibrosis.
With the development of gene therapy for various liver
diseases, intensive efforts have been made to design gene
Figure 3 Fibrosis analysis: histologic and molecular. A, shows a decrement in collagen content in cirrhotic animals treated with uPA plus MMP-8. 
B, liver sections Masson's stained in each experimental group, a) a representative histological image of a normal liver rat, in b-d cirrhotic animals treated 
with combinatorial gene therapy at 6, 8 and 10 days respectively. The histological images of f-h are representative of cirrhotic animals treated with 
irrelevant vector (Ad-β-Gal) at 6, 8 and 10 days, respectively, e) shows a control fibrotic liver injected with saline. C, Morphometric analysis indicates 
that animals treated with therapeutically gene therapy has a major recuperation at 6 to 10 days post-treatment (inducing a 55% of regression). D, TGF-
β, evaluated by semicuantitative RT-PCR, showed a major decrement in mRNA at 8 days after treatment with Ad-uPA plus Ad-MMP-8 as compared 
with irrelevant control. N, normal; F, fibrotic.
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pathways, regulate the fibrinolytic homeostasis and re-
establishment of organic functional activity [12,18].
As uPA was able to induce ECM-degradation, we deter-
mined if this fibrosis regression was induced by an
increase in MMP-2 and MMP9 activity, which exacerbate
type I collagen degradation. We also demonstrated that
infusion with uPA gene to the animal model produced
increased expression of uPA protein, resulting in signifi-
cant attenuation of fibrosis.
Stimulation of hepatocyte regeneration is one of the
essential strategies for the treatment of hepatic fibrosis.
HGF is considered to be the strongest hepatocyte prolif-
erative agent to date and is able to exhibit a plethora of
effects in hepatic fibrosis. HGF could stimulate hepato-
cyte mitosis, inhibit hepatocyte apoptosis, and suppress
the expression of TGF-β1, resulting in inhibition of pro-
liferation and activation of HSC in the fibrotic liver [19].
It could be inferred that HGF is able to stimulate hepato-
cyte regeneration and remodel the deranged cirrhotic tis-
sue as well, offering the substantial potential for gene
therapy of liver cirrhosis [20]. The synergistic antifibrotic
effect on hepatic fibrosis was attributed to some potential
mechanisms. First, uPA increases gene expression of
HGF and had a proliferative effect on hepatocytes [14,20].
Overexpression of HGF could also result in suppression
of TGF-β1 in the hepatic wound-healing response.
At present, combinational gene delivery seemed to be
one of the most important developments in gene therapy.
Yang and his colleagues reported that combinational gene
therapy using IL-12, pro-IL-18, and IL-1β converting
enzyme (ICE) cDNA expression vectors simultaneously
delivered via a gene gun could significantly augment anti-
tumor effects by generating increased levels of bioactive
IL-18 and consequently IFN-γ. Similarly, Lyn et al. have
shown the therapeutic effect of combination of uPA plus
Figure 4 Human transgenes detection and fibrinolytic activities. Panels A and B show uPA and MMP-8 proteins in cirrhotic animals, both control 
and experimental (2nd through 10th days) detected by immunohistochemistry, indicating percentage of positive cells. C, transgenes activity, shows 
major activity of both trangenes (uPA and MMP-8) at 4 days after treatment. D, both enzymes (MM-2 and MM-9) increment their functional activities 
only in the cirrhotic animals treated with Ad-uPA plus Ad-MMP-8 and the maximum activity was at 4 days post-treatment.
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HGF gene into primary cultured hepatocytes and uPA
gene to hepatic stellate cell (HSC) to investigate the effect
on the biological character of cells. Transfection of exoge-
nous HGF gene stimulated hepatocyte proliferation.
Human uPA gene decreased the amount of type I and III
collagens accompanied with increased expression of
matrix metalloproteinase-2 in vitro. In vivo, the area of
ECM in the fibrotic liver decreased to 72% in Ad-HGF-
treated rats, 64% in the Ad-uPA-treated group, and 51%
in bi-genes transfection. Moreover, immunohistochemi-
cal staining of collagen types I and III revealed that com-
binational genes delivery exerted more effect on reversal
of hepatic fibrosis than mono-gene transfection. This
study indicated that simultaneous delivery genes could
confer synergistic effect on hepatic fibrosis [11].
According to our study, the most interesting finding
was that the combinational delivery of uPA and MMP-8
genes was more effective than mono-gene therapy in
reversal of fibrosis and is in agreement with Lyn et al.
respect to sinergystic effect of fibrosis regression (Figure
3), increment of functional activity of MMP2 and MMP-9
(Figure 4D) involved in the degradation of the excessive
collagens deposition, in a persistent hepatic fibrosis ani-
mal model intoxicated continuosly with CCL4.
In fact, even if the liver has an enormous functional
reserve and a unique regenerative capacity, cirrhotic liver
regenerates less actively than normal liver. The discovery
of agents that could sustain cirrhotic liver regeneration
would thus have important clinical implications. Osawa
et al. reported that HGF plus truncated type II transform-
ing growth factor-β receptor (TβRII), stimulates liver
regeneration, accelerates restoration of hepatic function,
and prevents progression of liver fibrosis. Tiberio et al.
have shown incremented the survival in decompensated
Figure 5 Cellular proliferation and survival. A, PCNA protein (regeneration index) shows increment only with the treatment of combinatorial gene 
therapy at 2-4 days post treatment. B, gene expression of HGF and c-met determined by semiquantitative RT-PCR that indicate a light increment of 
both genes on the animals treated with Ad-uPA plus Ad-MMP-8 to respect Ad-β-Gal. C, activated HSC (α-SMA+) show significant decrement after 2 
days of treatment with therapeutically gene therapy. D, Survival analysis (Kaplan Meier) of cirrhotic animals in each experimental group. Increment of 
survival (60 days) in the animals receiving the combined gene therapy is noticeable.
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[17].
Our results provide evidence that uPA plus MMP-8
treatment reduces mortality. We speculate that the
increased survival of cirrhotic rats may in part result
from uPA-mediated enhancement and acceleration of
liver regeneration that we directly demonstrated by incre-
ments in HGF, c-met and PCNA gene expression in rats
affected by cirrosis and liver function, which included
serum levels of ALT and AST, improved significantly in
therapeutic gene therapy-treated rats compared with all
other groups.
Indeed, accelerated recovery of the liver mass, and sig-
nificant increments of ECM-degradation contributed to
survival of cirrhotic animals. Combinational delivery of
uPA plus MMP-8 genes would be reflected in a significa-
tive increment in survival time (Figure 5D), which had
advantages over the treatment with either Ad-huPA or
Ad-MMP-8 alone. Our findings suggested that simulta-
neous delivery of two or multiple and functional thera-
peutic genes, can provide a new biotechnological
weapons for the treatment of hepatic fibrosis.
In general, our results suggest that the combination of
uPA and MMP-8 gene therapy may increase the possibil-
ity of survival in cirrhotic animals by improving fibrosis,
function, and hepatocyte regeneration.
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